More bad news for Sarep­ta; No­var­tis, Mi­crosoft join forces in AI pact

→ Sarep­ta $SRPT is still feel­ing the heat. A lit­tle more than a month af­ter the FDA threw an un­ex­pect­ed sur­prise re­jec­tion for the com­pa­ny’s ap­pli­ca­tion for an ac­cel­er­at­ed ap­proval of its Duchenne MD drug, golodirsen, the com­pa­ny faced more bad news to­day. A ri­val com­pa­ny in Japan, NS Phar­ma, said that it had sub­mit­ted the nec­es­sary pa­per­work need­ed for ap­proval of their new drug, vil­to­larsen, to treat Duchenne MD for chil­dren born with the dis­or­der caused by a mu­ta­tion in the DNA se­quence ex­on 53. Ac­cord­ing to a STAT re­port, NS Phar­ma ex­pects vil­to­larsen to be ap­proved in the US by the mid­dle of 2020, if not soon­er — bar­ring any set­backs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER